Short-lived immunity after 17DD Yellow Fever single dose indicates that booster vaccination may be required to guarantee protective immunity in children

• Autor(es): Campi-Azevedo, Ana Carolina ; Reis, Laise Rodrigues ; Peruhype-Magalh?es, Venessa ; Reis, Jordana Grazziela Coelho dos ; Antonelli, Lis Ribeiro ; Fonseca, Cristina Toscano ; Costa-Pereira, Christiane ; Souza-Fagundes, Elaine Maria ; Costa-Rocha, Ismael Artur da ; Mambrini, Juliana Vaz de Melo ; Lemos, Jandira Aparecida Campos ; Ribeiro, Jos? Geraldo Leite ; Caldas, Iramaya Rodrigues ; Camacho, Luiz Ant?nio Bastos ; Maia, Maria de Lourdes de Sousa ; Noronha, Tatiana Guimar?es de ; Lima, Sheila Maria Barbosa de ; Sim?es, Marisol ; Freire, Marcos da Silva ; Martins, Reinaldo de Menezes ; Homma, Akira ; Tauil, Pedro Luiz ; Vasconcelos, Pedro Fernando da Costa ; Romano, Alessandro Pecego Martins ; Domingos, Carla Magda ; Teixeira-Carvalho, Andr?a ; Martins Filho, Olindo Assis
• Data: 2019
• Origem: Oasisbr
• Assunto(s): Febre Amarela; V?rus da Febre Amarela / patogenicidade; Vacina??o; Vacina 17DD; Mem?ria celular; Anticorpos Neutralizantes; Imunidade Celular
• Tipo de Documento: Artigo científico
• Idioma: Inglês

Descrição

Funda??o de Amparo ? Pesquisa do Estado de Minas Gerais (FAPEMIG), BioManguinhos/FIOCRUZ, PROEP/IRR/FIOCRUZ, Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico-CNPq

Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil.

Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil.

Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil.

Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil.

Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil.

Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil.

Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil.

Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil.

Universidade Federal de Minas Gerais. Departamento de Fisiologia e Biof?sica. Belo Horizonte, MG, Brasil.

Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil

Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil

Secretaria Municipal de Sa?de de Belo Horizonte. Belo Horizonte, MG, Brasil.

Secretaria do Estado de Sa?de de Minas Gerais. Belo Horizonte, MG, Brasil.

Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil.

Funda??o Oswaldo Cruz. Escola Nacional de Sa?de P?blica Sergio Arouca. Rio de Janeiro, RJ, Brasil.

Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiol?gicos. Rio de Janeiro, RJ, Brasil.

Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiol?gicos. Rio de Janeiro, RJ, Brasil.

Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiol?gicos. Rio de Janeiro, RJ, Brasil.

Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiol?gicos. Rio de Janeiro, RJ, Brasil.

Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiol?gicos. Rio de Janeiro, RJ, Brasil.

Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiol?gicos. Rio de Janeiro, RJ, Brasil.

Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiol?gicos. Rio de Janeiro, RJ, Brasil.

Funda??o Oswaldo Cruz. Instituto de Tecnologia em Imunobiol?gicos. Rio de Janeiro, RJ, Brasil.

Universidade de Bras?lia. Faculdade de Medicina. Bras?lia, DF, Brasil.

Minist?rio da Sa?de. Secretaria de Vigil?ncia em Sa?de. Instituto Evandro Chagas. Ananindeua, PA, Brasil.

Minist?rio da Sa?de. Secretaria de Vigil?ncia em Sa?de. Departamento de Imuniza??o e Doen?as Transmiss?veis. Bras?lia, DF, Brasil.

Minist?rio da Sa?de. Secretaria de Vigil?ncia em Sa?de. Programa Nacional de Imuniza??es. Bras?lia, DF, Brasil.

Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil.

Funda??o Oswaldo Cruz. Instituto Ren? Rachou. Belo Horizonte, MG, Brasil.

The Yellow Fever (YF) vaccination is recommended for people living in endemic areas and represents the most effective strategy to reduce the risk of infection. Previous studies have warned that booster regimens should be considered to guarantee the long-term persistence of 17DD-YF-specific memory components in adults living in areas with YF-virus circulation. Considering the lower seroconversion rates observed in children (9-12 months of age) as compared to adults, this study was designed in order to access the duration of immunity in single-dose vaccinated children in a 10-years cross-sectional time-span. The levels of neutralizing antibodies (PRNT) and the phenotypic/functional memory status of T and B-cells were measured at a baseline, 30-45 days, 1, 2, 4, 7, and 10 years following primary vaccination. The results revealed that a single dose induced 85% of seropositivity at 30-45 days and a progressive time-dependent decrease was observed as early as 2 years and declines toward critical values (below 60%) at time-spans of ?4-years. Moreover, short-lived YF-specific cellular immunity, mediated by memory T and B-cells was also observed after 4-years. Predicted probability and resultant memory analysis emphasize that correlates of protection (PRNT; effector memory CD8+ T-cells; non-classical memory B-cells) wane to critical values within ?4-years after primary vaccination. Together, these results clearly demonstrate the decline of 17DD-YF-specific memory response along time in children primarily vaccinated at 9-12 months of age and support the need of booster regimen to guarantee the long-term persistence of memory components for children living in areas with high risk of YF transmission.